Status:
UNKNOWN
ILF With/Without Cisplatin for Advanced Gastric Cancer
Lead Sponsor:
Gachon University Gil Medical Center
Conditions:
Stomach Neoplasm
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.
Detailed Description
Irinotecan, in combination with 5-FU or cisplatin, clearly demonstrated efficacy against gastric cancer. A previous randomized study of ILF regimen versus IP in patients with AGC showed that the ILF p...
Eligibility Criteria
Inclusion
- Histologically proven gastric adenocarcinoma
- Advanced, metastatic or recurrent
- ECOG performance status 0 to 2
- No prior chemotherapy
- Measurable or evaluable indicator lesion(s)
- Normal marrow, hepatic and renal functions
- Provision of written informed consent
Exclusion
- Active infection, bleeding or severe comorbidities
- Pregnant or breastfed women
- Active CNS metastasis
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00320294
Start Date
February 1 2005
End Date
March 1 2007
Last Update
March 12 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gachon University Gil Medical Center
Incheon, South Korea, 405 760